Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medtronic PLC

Latest From Medtronic PLC

Unlocking Legalities: Antitrust Risk Rises In China

A $17.2m fine Chinese regulators imposed on Medtronic may just be the tip of the enforcement iceberg as the country attempts to discipline overseas manufacturers who break new antitrust laws.

China Legal Issues

Number To Know…3

Only three leadless pacemakers have been CE marked to date, as revealed following the publication of recent UK guidelines on how to evaluate such products.

Cardiology Regulation

Symetis Seeks $60m IPO To Make A Splash In Structural Heart

Symetis, Europe's No. 4 in the TAVR market, hopes its initial public offering, with a price range of €26 to €32 per share on Euronext Paris, will help build on its recent transcatheter mitral valve repair acquisition and its growing market position in TAVR.

Cardiology Financing

ACC 2017: SURTAVI Supports Intermediate-Risk Intervention For Medtronic's CoreValve

In an interview with Medtech Insight, the lead investigator of SURTAVI, an ongoing trial of Medtronic's CoreValve in intermediate risk patents, says transcatheter aortic valve is continuously improving and will probably soon be indicated for even low-risk patients, but that surgical valve replacement will have an important role to play for the foreseeable future.

Cardiology Clinical Trials
See All

Company Information